| Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical … HI Scher, S Halabi, I Tannock, M Morris, CN Sternberg, MA Carducci, ... Journal of clinical oncology: official journal of the American Society of …, 2008 | 2385 | 2008 |
| A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer RS Sandler, S Halabi, JA Baron, S Budinger, E Paskett, R Keresztes, ... New England Journal of Medicine 348 (10), 883-890, 2003 | 1479 | 2003 |
| Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ... Journal of Clinical Oncology 34 (12), 1402, 2016 | 1299 | 2016 |
| Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study PW Kantoff, S Halabi, M Conaway, J Picus, J Kirshner, V Hars, D Trump, ... Journal of Clinical Oncology 17 (8), 2506-2506, 1999 | 1159 | 1999 |
| Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 BI Rini, S Halabi, JE Rosenberg, WM Stadler, DA Vaena, SS Ou, L Archer, ... Journal of Clinical Oncology 26 (33), 5422, 2008 | 1155 | 2008 |
| Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group GJ Bubley, M Carducci, W Dahut, N Dawson, D Daliani, M Eisenberger, ... Journal of Clinical Oncology 17 (11), 3461-3467, 1999 | 1141 | 1999 |
| Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 BI Rini, S Halabi, JE Rosenberg, WM Stadler, DA Vaena, L Archer, ... Journal of clinical oncology 28 (13), 2137, 2010 | 1017 | 2010 |
| Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer S Halabi, EJ Small, PW Kantoff, MW Kattan, EB Kaplan, NA Dawson, ... Journal of Clinical Oncology 21 (7), 1232-1237, 2003 | 811 | 2003 |
| Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial TK Choueiri, S Halabi, BL Sanford, O Hahn, MD Michaelson, MK Walsh, ... Journal of Clinical Oncology 35 (6), 591, 2017 | 789 | 2017 |
| Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583) EJ Small, S Halabi, NA Dawson, WM Stadler, BI Rini, J Picus, P Gable, ... Journal of clinical oncology 22 (6), 1025-1033, 2004 | 653 | 2004 |
| Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials BF Cole, RF Logan, S Halabi, R Benamouzig, RS Sandler, MJ Grainge, ... JNCI: Journal of the National Cancer Institute 101 (4), 256-266, 2009 | 570 | 2009 |
| American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma RA Kyle, GC Yee, MR Somerfield, PJ Flynn, S Halabi, S Jagannath, ... Journal of Clinical Oncology 25 (17), 2464-2472, 2007 | 524 | 2007 |
| Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018 | 519 | 2018 |
| Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate … WK Kelly, S Halabi, M Carducci, D George, JF Mahoney, WM Stadler, ... Journal of Clinical Oncology 30 (13), 1534, 2012 | 501 | 2012 |
| Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663 ME Taplin, B Rajeshkumar, S Halabi, CP Werner, BA Woda, J Picus, ... Journal of clinical oncology 21 (14), 2673-2678, 2003 | 497 | 2003 |
| Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer S Halabi, CY Lin, WK Kelly, KS Fizazi, JW Moul, EB Kaplan, MJ Morris, ... Journal of Clinical Oncology 32 (7), 671, 2014 | 490 | 2014 |
| Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer S Halabi, WK Kelly, H Ma, H Zhou, NC Solomon, K Fizazi, CM Tangen, ... Journal of clinical oncology 34 (14), 1652, 2016 | 412 | 2016 |
| Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial AJ Armstrong, S Halabi, T Eisen, S Broderick, WM Stadler, RJ Jones, ... The Lancet Oncology 17 (3), 378-388, 2016 | 408 | 2016 |
| Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780 DM Savarese, S Halabi, V Hars, WL Akerley, ME Taplin, PA Godley, ... Journal of Clinical Oncology 19 (9), 2509-2516, 2001 | 408 | 2001 |
| Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer W Xie, MM Regan, M Buyse, S Halabi, PW Kantoff, O Sartor, H Soule, ... Journal of Clinical Oncology 35 (27), 3097, 2017 | 394 | 2017 |
Michael J. MorrisMemorial Sloan-Kettering Cancer CenterVerified email at mskcc.org
